MA35507B1 - Protéines à double fonction pour le traitement de troubles du métabolisme - Google Patents
Protéines à double fonction pour le traitement de troubles du métabolismeInfo
- Publication number
- MA35507B1 MA35507B1 MA36823A MA36823A MA35507B1 MA 35507 B1 MA35507 B1 MA 35507B1 MA 36823 A MA36823 A MA 36823A MA 36823 A MA36823 A MA 36823A MA 35507 B1 MA35507 B1 MA 35507B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- metabolic disorders
- dual function
- metabolic
- related disorders
- Prior art date
Links
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 230000009977 dual effect Effects 0.000 title 1
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000002503 metabolic effect Effects 0.000 abstract 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 abstract 1
- 108010011459 Exenatide Proteins 0.000 abstract 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 1
- 229960001519 exenatide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne l'identification de protéines de nouvelles protéines comprenant le facteur de croissance des fibroblastes 21 (fgf21) et d'autres régulateurs du métabolisme, y compris des variants de ceux-ci, connus pour améliorer les profils métaboliques chez des sujets auxquels ils sont administrés. L'invention concerne également des procédés de traitement de troubles associés au fgf21, de troubles associés au glp-1 et de troubles associés à l'exendine-4, y compris des troubles du métabolisme.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161539290P | 2011-09-26 | 2011-09-26 | |
| PCT/US2012/057371 WO2013049234A2 (fr) | 2011-09-26 | 2012-09-26 | Protéines à double fonction pour le traitement de troubles du métabolisme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35507B1 true MA35507B1 (fr) | 2014-10-02 |
Family
ID=47023090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36823A MA35507B1 (fr) | 2011-09-26 | 2014-03-13 | Protéines à double fonction pour le traitement de troubles du métabolisme |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9458214B2 (fr) |
| EP (1) | EP2764019B1 (fr) |
| JP (1) | JP6152380B2 (fr) |
| KR (1) | KR102217254B1 (fr) |
| CN (2) | CN106432510A (fr) |
| AP (1) | AP2014007544A0 (fr) |
| AR (1) | AR088165A1 (fr) |
| AU (1) | AU2012316132A1 (fr) |
| BR (1) | BR112014007086A2 (fr) |
| CA (1) | CA2849760A1 (fr) |
| CL (1) | CL2014000737A1 (fr) |
| CO (1) | CO6920258A2 (fr) |
| CR (1) | CR20140141A (fr) |
| CU (1) | CU20140035A7 (fr) |
| EA (1) | EA201490697A1 (fr) |
| GT (1) | GT201400056A (fr) |
| IL (1) | IL231647A0 (fr) |
| MA (1) | MA35507B1 (fr) |
| MX (1) | MX350840B (fr) |
| PE (1) | PE20141542A1 (fr) |
| PH (1) | PH12014500659A1 (fr) |
| SG (1) | SG11201400596QA (fr) |
| TN (1) | TN2014000110A1 (fr) |
| TW (1) | TW201315742A (fr) |
| UY (1) | UY34347A (fr) |
| WO (1) | WO2013049234A2 (fr) |
| ZA (1) | ZA201401699B (fr) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807552A1 (fr) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Acides nucleiques modifies et leurs procedes d'utilisation |
| LT4108671T (lt) | 2010-10-01 | 2025-01-10 | Modernatx, Inc. | Modifikuoti nukleozidai, nukleotidai, nukleorūgštys bei jų panaudojimas |
| US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
| UA118744C2 (uk) | 2011-07-01 | 2019-03-11 | ЕнДжиЕм БАЙОФАРМАСЬЮТІКАЛЗ, ІНК. | Химерний пептид, композиція, що його містить, його застосування і способи лікування порушень і захворювань обміну речовин |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| UY34346A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
| TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
| SMT202200229T1 (it) | 2011-10-03 | 2022-07-21 | Modernatx Inc | Nucleosidi, nucleotidi e acidi nucleici modificati e loro usi |
| RU2649364C2 (ru) | 2011-12-16 | 2018-04-02 | Модерна Терапьютикс, Инк. | Составы на основе модифицированного нуклеозида, нуклеотида и нуклеиновой кислоты |
| AU2013243954A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| CN108524919A (zh) | 2012-05-17 | 2018-09-14 | 延伸生物科学股份有限公司 | 用于改进的药物递送的载体 |
| AR092076A1 (es) * | 2012-08-22 | 2015-03-18 | Lilly Co Eli | Proteinas homodimericas |
| EP2892919A1 (fr) * | 2012-09-07 | 2015-07-15 | Sanofi | Protéines de fusion pour traiter un syndrome métabolique |
| HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
| AU2013352363B2 (en) | 2012-11-28 | 2018-04-12 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| NZ630469A (en) | 2012-12-27 | 2017-02-24 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US20150335715A1 (en) * | 2013-01-03 | 2015-11-26 | Oramed Ltd. | Methods and compositions for treating nafld, hepatic steatosis, and sequelae thereof |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US10023626B2 (en) | 2013-09-30 | 2018-07-17 | Modernatx, Inc. | Polynucleotides encoding immune modulating polypeptides |
| BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
| WO2015065897A1 (fr) | 2013-10-28 | 2015-05-07 | Ngm Biopharmaceuticals, Inc. | Modèles de cancer et procédés associés |
| HUE050279T2 (hu) | 2014-01-24 | 2020-11-30 | Ngm Biopharmaceuticals Inc | Béta-klotho 2-es doménjéhez kötõdõ antitestek és azok alkalmazási módszerei |
| JP6712230B2 (ja) * | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
| CA2945240C (fr) * | 2014-04-11 | 2021-08-03 | Universite Catholique De Louvain | Ilots de porc transgenique et leurs utilisations pour le traitement du diabete |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| WO2016065052A1 (fr) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Conjugués insuline vitamine d |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| US9585934B2 (en) | 2014-10-22 | 2017-03-07 | Extend Biosciences, Inc. | Therapeutic vitamin D conjugates |
| KR102569907B1 (ko) | 2014-10-23 | 2023-08-24 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 펩티드 변이체를 포함하는 약제학적 조성물 및 그의 사용 방법 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| WO2017019957A2 (fr) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Protéines de liaison et leurs procédés d'utilisation |
| CN108463244B (zh) | 2015-08-04 | 2022-05-27 | 杜克大学 | 用于递送的基因编码的固有无序隐形聚合物及其使用方法 |
| TW201718629A (zh) * | 2015-09-25 | 2017-06-01 | 韓美藥品股份有限公司 | 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物 |
| KR102668200B1 (ko) | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| KR102670157B1 (ko) * | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
| LT3402811T (lt) | 2016-01-13 | 2022-06-10 | Novo Nordisk A/S | Egf(a) analogai su riebalų rūgščių pakaitais |
| JP7023518B2 (ja) | 2016-05-25 | 2022-02-22 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 分泌障害の処置のための方法および組成物 |
| US11467156B2 (en) | 2016-06-01 | 2022-10-11 | Duke University | Nonfouling biosensors |
| US11123438B2 (en) | 2016-08-19 | 2021-09-21 | Ampsource Biopharma Shanghai Inc. | Linker peptide for constructing fusion protein |
| CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技（上海）有限公司 | 双特异性抗体及其制备方法与用途 |
| CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| CN109890833A (zh) | 2016-09-14 | 2019-06-14 | 杜克大学 | 用于递送亲水性药物的基于三嵌段多肽的纳米粒子 |
| US11155584B2 (en) | 2016-09-23 | 2021-10-26 | Duke University | Unstructured non-repetitive polypeptides having LCST behavior |
| MX2019005380A (es) * | 2016-11-10 | 2019-08-12 | Yuhan Corp | Composicion farmaceutica que comprende proteinas de fusion para prevenir o tratar la hepatitis, la fibrosis hepatica y la cirrosis hepatica. |
| CA3041910A1 (fr) | 2016-11-22 | 2018-05-31 | Klotho Therapeutics, Inc. | Nouvelles proteines klotho recombinees et compositions et methodes les comprenant |
| AU2017382038A1 (en) * | 2016-12-22 | 2019-08-08 | Sanofi | FGF21 compound / GLP-1R agonist combinations with optimized activity ratio |
| US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
| CN108440668A (zh) * | 2017-02-16 | 2018-08-24 | 瑞阳(苏州)生物科技有限公司 | Fgf21与igf-1的融合蛋白及其应用 |
| EP4470551A3 (fr) * | 2017-03-14 | 2025-02-26 | Sunshine Lake Pharma Co., Ltd. | Protéines de fusion à double cible comprenant la partie fc d'une immunoglobuline |
| KR102664780B1 (ko) * | 2017-04-21 | 2024-05-13 | 주식회사유한양행 | 이중 작용 단백질 및 그의 유도체의 제조방법 |
| WO2018213320A1 (fr) | 2017-05-15 | 2018-11-22 | Duke University | Production recombinante de matériaux hybrides lipidiques-biopolymères qui s'auto-assemblent et encapsulent des agents |
| US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
| CA3068956A1 (fr) | 2017-07-19 | 2019-01-24 | Novo Nordisk A/S | Composes bifonctionnels |
| JP7296958B2 (ja) * | 2017-11-06 | 2023-06-23 | タケダ ファーマシューティカルズ ユーエスエー インコーポレイテッド | 手術前、手術中または手術後に投与するためのｇｌｐ－２類似体及びｇｌｐ－２ペプチボディ |
| CN115109166B (zh) * | 2017-11-24 | 2025-07-18 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
| CN111518770B (zh) * | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
| SI3727423T1 (sl) | 2017-12-22 | 2024-08-30 | Novartis Ag | Zdravljenje metaboličnih motenj z različicami fgf21 |
| CN110028587B (zh) * | 2018-01-11 | 2021-10-08 | 安源医药科技（上海）有限公司 | 用于调节血糖和脂质的增效型双功能蛋白 |
| US12296018B2 (en) | 2018-01-26 | 2025-05-13 | Duke University | Albumin binding peptide-drug (AlBiPeD) conjugates and methods of making and using same |
| US11679143B2 (en) | 2018-02-08 | 2023-06-20 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
| US12257308B2 (en) | 2018-04-30 | 2025-03-25 | Duke University | Stimuli-responsive PEG-like polymer-based drug delivery platform |
| CU24554B1 (es) * | 2018-05-07 | 2021-11-04 | Ct Inmunologia Molecular | Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1 |
| JP2021528422A (ja) * | 2018-06-21 | 2021-10-21 | サノフイＳａｎｏｆｉ | 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ |
| MX2021000016A (es) | 2018-07-03 | 2021-03-09 | Bristol Myers Squibb Co | Formulaciones de factor de crecimiento de fibroblastos (fgf-21). |
| WO2020028806A1 (fr) * | 2018-08-02 | 2020-02-06 | Duke University | Protéines de fusion à double agoniste |
| AU2019365212A1 (en) * | 2018-10-24 | 2021-04-29 | Shire-Nps Pharmaceuticals, Inc. | GLP-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| CN113454211A (zh) * | 2019-02-20 | 2021-09-28 | 诺和诺德股份有限公司 | 氨酰基-tRNA合成酶及其用途 |
| CN114853908B (zh) * | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
| EP4028413A1 (fr) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Protéines de fusion de ca2-il15 pour une régulation accordable |
| EP4085077A4 (fr) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Protéines de fusion de glp-1 et de gdf15 et leurs conjugués |
| CN115322794B (zh) * | 2020-01-11 | 2025-09-19 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| US11981718B2 (en) * | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
| CA3181300A1 (fr) * | 2020-06-03 | 2021-12-09 | Christoffer CLEMMENSEN | Conjugues d'antagoniste de nmdar agoniste du glp1r |
| WO2022002408A1 (fr) * | 2020-07-02 | 2022-01-06 | Sanofi | Protéines hybrides fgf21/agoniste de glp-1r |
| CN113105561B (zh) * | 2021-04-30 | 2021-12-03 | 江南大学 | 一种双靶点融合蛋白的制备方法和应用 |
| KR102631925B1 (ko) * | 2021-06-10 | 2024-02-01 | 토드제약 주식회사 | 신규 fgf21 변이체 개발 및 이의 생산기법과 용도 |
| WO2023099723A1 (fr) * | 2021-12-02 | 2023-06-08 | Københavns Universitet | Conjugués peptide-médicament pour le traitement de maladies neurodégénératives |
| IL319526A (en) | 2022-09-30 | 2025-05-01 | Extend Biosciences Inc | Long-acting parathyroid hormone |
| JP2025537240A (ja) * | 2022-11-07 | 2025-11-14 | ビーピー アセット ナイン、インコーポレイテッド | Ｎａｓｈ治療のためのｆｇｆ２１タンパク質変異体 |
| WO2024123812A1 (fr) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Protéines de fusion pour le traitement de maladies cardiométaboliques |
| CN115991793A (zh) * | 2023-01-16 | 2023-04-21 | 上海民为生物技术有限公司 | 具有多重活性的融合蛋白及其应用 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| EP0206448B1 (fr) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hémoglobine liée à un poly(oxyde d'alkylène) |
| EP0305387B2 (fr) | 1986-05-05 | 1996-08-28 | The General Hospital Corporation | Hormone insulinotrope |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3889853D1 (de) | 1987-11-05 | 1994-07-07 | Hybritech Inc | Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik. |
| JP2989002B2 (ja) | 1988-12-22 | 1999-12-13 | キリン―アムジエン・インコーポレーテツド | 化学修飾顆粒球コロニー刺激因子 |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| WO1993015722A1 (fr) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Liberation controlee de produits pharmaceutiques a partir de microparticules poreuses preformees |
| US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| HU227021B1 (en) | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
| US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
| DE60030769T2 (de) | 1999-12-23 | 2007-10-25 | Zymogenetics, Inc., Seattle | Verfahren zur behandlung von entzündungen |
| DK2128246T3 (da) | 2001-04-19 | 2014-05-12 | Univ California | Fremgangsmåder og sammensætninger til fremstilling af ortogonale tRNA-aminoacyl-tRNA-syntetasepar. |
| US8029789B2 (en) * | 2003-11-13 | 2011-10-04 | Hanmi Holdings Co., Ltd. | Method for the mass production of immunoglobulin constant region |
| KR20060135648A (ko) | 2003-12-10 | 2006-12-29 | 일라이 릴리 앤드 캄파니 | 섬유모세포 성장인자 21의 뮤테인 |
| AU2005289685B2 (en) | 2004-09-24 | 2009-07-16 | Amgen Inc. | Modified Fc molecules |
| US20080261875A1 (en) * | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
| HRP20120522T1 (hr) | 2007-03-30 | 2012-08-31 | Ambrx | Modificirani fgf-21 polipeptidi i njihova uporaba |
| JP2010535781A (ja) | 2007-08-03 | 2010-11-25 | イーライ リリー アンド カンパニー | 肥満に対する処置 |
| WO2010042747A2 (fr) | 2008-10-10 | 2010-04-15 | Amgen Inc. | Mutants fgf21 et leurs utilisations |
| KR101316159B1 (ko) | 2008-10-24 | 2013-10-15 | 아이알엠 엘엘씨 | 생합성적으로 생성된 피롤린-카르복시-리신, 및 피롤린-카르복시-리신 및 피롤리신 잔기의 화학적 유도체화를 통한 부위 특이적 단백질 변형 |
| WO2010065439A1 (fr) | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants de facteurde croissance 21 du fibroblaste |
| WO2010068735A1 (fr) | 2008-12-10 | 2010-06-17 | Glaxosmithkline Llc. | Compositions pharmaceutiques |
| JP5599822B2 (ja) | 2009-01-23 | 2014-10-01 | ノヴォ ノルディスク アー／エス | アルブミンバインダーａ−ｂ−ｃ−ｄ−ｅ−を有するｆｇｆ２１誘導体及びそれらの使用 |
| CN101812474A (zh) * | 2009-02-25 | 2010-08-25 | 李慎涛 | 骨保护素-热休克蛋白65融合蛋白的制备及其应用 |
| EP2427207B1 (fr) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Mutants de fgf21 et leurs utilisations |
| JO3469B1 (ar) * | 2009-05-05 | 2020-07-05 | Amgen Inc | طافرات fgf21 واستخداماتها |
| WO2010142665A1 (fr) | 2009-06-11 | 2010-12-16 | Novo Nordisk A/S | Combinaisons de glp-1 et de fgf21 pour le traitement du diabète de type 2 |
| CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
| CN101993496B (zh) | 2009-08-20 | 2013-06-05 | 重庆富进生物医药有限公司 | 双重调节血糖血脂融合蛋白及其制法和用途 |
| CA2785139A1 (fr) | 2009-12-22 | 2011-06-30 | Novartis Ag | Proteine hybride tetravalente a region constante d'anticorps anti-cd-47 a utiliser en therapie |
| EP2460527A1 (fr) | 2010-01-21 | 2012-06-06 | Sanofi | Composition pharmaceutique pour le traitement d'un syndrome métabolique |
| US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
| TW201315742A (zh) | 2011-09-26 | 2013-04-16 | Novartis Ag | 治療代謝病症之雙功能蛋白質 |
| UY34346A (es) | 2011-09-26 | 2013-04-30 | Novartis Ag | Proteínas de fusión para tratar trastornos metabólicos |
| JP6712230B2 (ja) | 2014-03-11 | 2020-06-17 | ノバルティス アーゲー | リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法 |
-
2012
- 2012-09-25 TW TW101135181A patent/TW201315742A/zh unknown
- 2012-09-25 UY UY0001034347A patent/UY34347A/es not_active Application Discontinuation
- 2012-09-25 US US13/626,207 patent/US9458214B2/en not_active Expired - Fee Related
- 2012-09-26 EP EP12773169.3A patent/EP2764019B1/fr active Active
- 2012-09-26 EA EA201490697A patent/EA201490697A1/ru unknown
- 2012-09-26 WO PCT/US2012/057371 patent/WO2013049234A2/fr not_active Ceased
- 2012-09-26 SG SG11201400596QA patent/SG11201400596QA/en unknown
- 2012-09-26 AP AP2014007544A patent/AP2014007544A0/xx unknown
- 2012-09-26 CN CN201610821947.8A patent/CN106432510A/zh active Pending
- 2012-09-26 CA CA2849760A patent/CA2849760A1/fr not_active Abandoned
- 2012-09-26 PH PH1/2014/500659A patent/PH12014500659A1/en unknown
- 2012-09-26 MX MX2014003676A patent/MX350840B/es active IP Right Grant
- 2012-09-26 BR BR112014007086A patent/BR112014007086A2/pt not_active Application Discontinuation
- 2012-09-26 KR KR1020147010943A patent/KR102217254B1/ko not_active Expired - Fee Related
- 2012-09-26 JP JP2014532112A patent/JP6152380B2/ja not_active Expired - Fee Related
- 2012-09-26 AU AU2012316132A patent/AU2012316132A1/en not_active Abandoned
- 2012-09-26 AR ARP120103552A patent/AR088165A1/es unknown
- 2012-09-26 PE PE2014000419A patent/PE20141542A1/es not_active Application Discontinuation
- 2012-09-26 CN CN201280057819.0A patent/CN104024273B/zh not_active Expired - Fee Related
-
2014
- 2014-03-07 ZA ZA2014/01699A patent/ZA201401699B/en unknown
- 2014-03-12 TN TNP2014000110A patent/TN2014000110A1/en unknown
- 2014-03-13 MA MA36823A patent/MA35507B1/fr unknown
- 2014-03-20 IL IL231647A patent/IL231647A0/en unknown
- 2014-03-25 CL CL2014000737A patent/CL2014000737A1/es unknown
- 2014-03-26 CU CU2014000035A patent/CU20140035A7/es unknown
- 2014-03-26 CO CO14064524A patent/CO6920258A2/es unknown
- 2014-03-26 GT GT201400056A patent/GT201400056A/es unknown
- 2014-03-26 CR CR20140141A patent/CR20140141A/es unknown
-
2016
- 2016-08-26 US US15/248,712 patent/US10669323B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35507B1 (fr) | Protéines à double fonction pour le traitement de troubles du métabolisme | |
| MA35437B1 (fr) | Proteines de fusion pour le traitement de troubles du metabolisme | |
| MA34710B1 (fr) | Procede de traitement des troubles associes au fgf21 | |
| EA200700886A1 (ru) | Соединение тиадиазола и его применение | |
| PH12013500615A1 (en) | Phosphospecific antibodies recognising tau | |
| EP4603144A3 (fr) | Administration peripherique de genes du cns utilisant des vecteurs aav | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| UA112743C2 (uk) | Терапевтичний dll4-зв'язувальний білок | |
| EA201290849A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EP4364801A3 (fr) | Dosage optimisé de diaminophénothiazines dans des populations | |
| EP2563794A4 (fr) | Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques | |
| EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
| EP4279127A3 (fr) | Facteur de différentiation de croissance 15 en tant que biomarqueur de metformine | |
| MA45172B1 (fr) | Arn modifié codant pour des polypeptides vegf-a, formulations et utilisations associées | |
| WO2023178280A3 (fr) | Compositions et méthodes de modulation de l'expression de l'alpha-synucléine | |
| EA202190334A1 (ru) | Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением | |
| WO2012173781A3 (fr) | Méthodes de traitement des troubles du métabolisme du glucose | |
| MA37640A1 (fr) | Protéines du facteur de croissance des fibroblastes 21 | |
| TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders | |
| UA111587C2 (uk) | Сполуки для лікування захворювань, пов'язаних з амілоїдними або амілоїдоподібними білками | |
| TH145764A (th) | วิธีการสำหรับการบำบัดความผิดปกติที่เกี่ยวข้องกับ fgf21 | |
| ATE535246T1 (de) | Zusammensetzung zur behandlung von erkrankungen des zentralen nervensystems | |
| TH1401006878A (th) | รีคอมบิแนนท์ อะดีโน-แอสโซซิเอเทดไวรัส (rAAV) เว็คเตอร์สำหรับใช้ในการบำบัดรักษาโรคการสร้างหลอดเลือดใหม่ของตาในผู้ป่วย ที่เคยได้รับสารยับยั้ง VEGF | |
| UA92465C2 (ru) | Терапевтические применения ингибиторов rtp801 |